GAVI Alliance funds vaccines for cervical cancer in developing countries
More than 180,000 girls in eight developing countries are set to receive protection against the leading cause of cervical cancer thanks to human papillomavirus (HPV) vaccines funded by the GAVI Alliance.
In an announcement made on World Cancer Day, the Alliance confirmed that Ghana, Kenya, Lao PDR, Madagascar, Malawi, Niger, Sierra Leone and Tanzania will become the first countries to receive GAVI support to start HPV vaccine demonstration programs.
UNICEF, a key GAVI partner, will procure the vaccines following a competitive tender process that is currently being completed. Merck & Co (NYSE: MRK) and GlaxoSmithKline (LSE: GSK) are currently the only two manufacturers who have prequalified HPV vaccines Gardasil and Cervarix, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze